What Researchers Miss When Biostorage Is an Afterthought

Biostorage Is Not a Footnote—It’s a Foundation

Too often, biospecimen storage is treated as the final line item on a checklist—a logistical box to tick after the hard work of study design, recruitment, and sample collection. But when biostorage is an afterthought, the consequences ripple far beyond the freezer. Delays, data loss, and compliance issues frequently trace back to unplanned or poorly managed storage workflows.

In an era where clinical trials rely on increasingly complex assays, sensitive biomarkers, and longitudinal data collection, high-quality biostorage is not a back-end task. It’s an infrastructure decision. Without it, even the most carefully designed study can fall apart.

What Happens When Storage Isn’t Part of the Study Design

When storage planning is delayed or outsourced to non-integrated vendors, pre-analytical variability increases. Samples may be subjected to different freeze/thaw cycles, inconsistently logged, or stored under conditions that don’t align with their eventual assay needs. The result? Lost integrity, inconsistent data, and missed endpoints.

One real-world example comes from the ALLHAT trial, one of the largest hypertension studies in the U.S. Though the trial succeeded in enrolling over 42,000 participants, many of its stored specimens became unsuitable for biomarker analysis due to suboptimal long-term storage protocols during the early phases. As noted in subsequent reviews, the lack of upfront planning for sample preservation limited post-trial insights into metabolic and genetic risk factors—excluding data that could have enhanced long-term cardiovascular management strategies¹.

In another case, a Phase II oncology study involving a novel immunotherapy experienced a six-month delay due to missing chain-of-custody documentation for over 120 tumor samples stored offsite. Investigators were unable to verify sample stability or confirm conditions for downstream analysis, rendering a portion of the dataset unusable. The cost: re-consenting patients, repeating biopsies, and delaying the next clinical phase.

The False Economy of “Just Store It”

When budgets are tight, teams often default to the lowest-cost option for sample storage: a basic freezer in a university lab, or an external vendor offering minimal compliance documentation. This may seem harmless—until it’s not.

Storage without audit trails, digital metadata, or redundancy introduces risks that can’t always be fixed. In one instance reported in Nature, researchers working on a longitudinal Alzheimer’s biomarker study discovered that one third of stored plasma samples had undergone unrecorded thawing during a facility move. The biomarker assay results—already in the final stages of analysis—were thrown into question².

This isn’t just about quality control. In regulated environments, poor biostorage planning can become a legal issue. FDA guidance for human biospecimens in clinical trials requires documentation of storage conditions, handling protocols, and traceability of every specimen used in regulated submissions³. Failing to meet those expectations can invalidate an otherwise successful dataset.

How to Bake Storage Into Study Planning

The best time to think about biostorage is not after collection—but during protocol development. Storage formats, temperature requirements, metadata capture, retrieval timelines, and reanalysis plans should all be aligned with the intended downstream assays and regulatory needs.

For example, if PBMCs will be stored for immunophenotyping and RNA analysis, protocols should include cryopreservation in DMSO-containing media, followed by storage in vapor-phase liquid nitrogen. If serum will be used for ELISA-based cytokine profiling, ultra-low temperature (-80°C) freezers should be monitored for temperature excursions and require backup power.

These decisions influence not just specimen quality, but the interpretability of your data. Pre-analytical variation remains one of the most significant sources of error in translational studies—and much of it stems from poor planning around storage.

Storage That Matches the Science

At Avrok, biostorage is engineered as part of a larger precision ecosystem. From procurement to processing and storage, all workflows are aligned around the scientific use case. That means storage formats are selected based on assay compatibility. Chain-of-custody and metadata are digitally logged from the outset. And every sample is housed in secure, monitored environments that preserve viability for future reanalysis.

Because we operate as both a specialty lab and storage provider, samples don’t have to be re-transported or re-annotated. That eliminates the handoffs that so often lead to integrity loss or regulatory gaps.

Store with Intention—or Risk the Data

Every biospecimen carries both a biological and an operational story. If storage is left to chance, that story can be cut short. But when storage is planned with the same care as the collection protocol or assay design, samples remain not just preserved—but potent.

Biostorage may not appear on every slide deck or publication title. But it is the quiet foundation of reproducibility, regulatory compliance, and scientific trust. Think of it not as an endpoint—but as the infrastructure that allows discovery to keep moving forward.

References

  1. Wright JT Jr, et al. ALLHAT trial final report. JAMA. 2002.

  2. Mandavilli A. Storage crisis imperils long-term studies. Nature. 2018;555(7695):14.

  3. FDA Guidance: Considerations for the Use of Human Biospecimens in Research. FDA.gov, 2020.